Shares of Stemline Therapeutics Inc. (NASDAQ:STML) were up 3.2% on Monday . The company traded as high as $8.73 and last traded at $8.70, with a volume of 172,583 shares. The stock had previously closed at $8.43.

A number of analysts have recently weighed in on STML shares. Jefferies Group reiterated a “buy” rating and set a $23.00 target price on shares of Stemline Therapeutics in a report on Monday, June 6th. Roth Capital restated a “buy” rating and issued a $32.00 price objective on shares of Stemline Therapeutics in a report on Tuesday, May 10th. Zacks Investment Research upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a report on Wednesday, July 6th. Finally, Wedbush restated an “outperform” rating and issued a $15.00 price objective on shares of Stemline Therapeutics in a report on Tuesday, August 23rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $19.31.

The company has a 50 day moving average of $7.45 and a 200 day moving average of $6.25. The company’s market capitalization is $155.08 million.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. Equities research analysts anticipate that Stemline Therapeutics Inc. will post ($2.11) EPS for the current fiscal year.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.